[A24-15] Fezolinetant (vasomotor symptoms in menopause) – Benefit assessment according to §35a Social Code Book V
Last updated 17.09.2024
Project no.:
A24-15
Commission:
Commission awarded on 01.03.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Reproductive health and birth
Menopausal women with moderate to severe vasomotor symptoms
- Patients for whom hormone therapy is an option and who have decided in favour of hormone replacement therapy after an individual risk-benefit assessment: added benefit not proven
- Patients for whom hormone therapy is not an option or those who have decided against therapy after an individual risk-benefit assessment: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
The current version 1.1 of the benefit assessment replaces version 1.0 published on 2024-05-02.
https://doi.org/10.60584/A24-15_V1.1_en
| Project no. | Title | Status |
|---|---|---|
| A24-69 | Fezolinetant (vasomotor symptoms in menopause) – Addendum to Project A24-15 | Commission completed |
Federal Joint Committee (G-BA)
2024-08-01 A G-BA decision was published.